Press Releases

This section of Viatris.com contains information that may not be suitable for use in all countries due to varied regulatory requirements, data protection requirements and practices or medical practices, and distinctions among product approval and commercial availability. The information contained in each news release or statement posted on this page is presented as of the date it was issued. The company undertakes no obligation to update the information for changes or subsequent events after the date it was originally issued.

Month Year

May 16, 2022

Viatris Publishes Sustainability Report Highlighting 2021 Progress, Achievements and Goals
May 9, 2022

Viatris Reports Strong First-Quarter 2022 Results
Apr 12, 2022

Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Nationwide Recall of One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), Due to the Potential for a Missing Label in the Batch
Apr 8, 2022

Viatris Inc. to Release First Quarter 2022 Financial Results on May 9, 2022
Mar 30, 2022
Sesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19
- Photos 1
Mar 17, 2022

Viatris Defeats Biogen's Attempt to Revive Tecfidera Patent
Mar 16, 2022

Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva
Mar 1, 2022

Viatris to Participate in Upcoming Investor Conferences
Feb 28, 2022

Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio with Biocon Biologics in Exchange for up to $3.335 Billion Representing an Attractive Multiple to Viatris of 16.5x the Company's Biosimilars 2022E Adjusted EBITDA(1), the First in a Series of Expected Initiatives Anticipated to Unlock up to an Additional $6 Billion in Pre-tax Proceeds by the End of 2023; Board of Directors Authorizes a Share Repurchase Program of up to $1 Billion, Maintaining Company Commitment to Return Capital to Shareholders
Feb 4, 2022

Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

Show per page

Localized information for Malaysia

Localized information for Malaysia

Leaving this page

Press Releases

Localized information for Malaysia

Localized information for Malaysia

Leaving this page

Leaving the Viatris site

Press Releases